Plants pause their growth during stress, then press play when conditions improve, helping them recover and live on to produce food, according to a new study published in New Phytologist. UBC ...
Roche’s phase III persevERA Breast Cancer study of giredestrant in combo with palbociclib ER-positive advanced breast cancer fails to meet its primary objective: Basel Tuesday, ...
Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination ...
The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a ...
US FDA accepts Roche’s NDA for giredestrant in ESR1-mutated, ER-positive advanced breast cancer: Basel Saturday, February 21, 2026, 11:00 Hrs [IST] Roche announced that the Unit ...
ERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbocicl ...
KOMODO-1 first-in-human clinical trial of BBI-940 open for enrollment $108 million in cash provides runway into the second half of 2028, through expected clinical proof-of-concept readout for KOMODO-1 ...
Filing acceptance based on phase III data showing giredestrant plus everolimus reduced the risk of disease progression or ...
Key opportunities in the prostate cancer market include innovation in androgen receptor degraders, radiopharmaceuticals, and immune-targeted therapies. Strategic collaborations and acquisitions ...
Bismuthene nanodiscs use mild heat to switch on gene editing that dismantles a tumor's heat defenses, creating a feedback loop that kills cancer cells more effectively.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results